News

The FDA approval was given on the basis of RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) Phase III trial data which showed that treatment with Afinitor more than doubled

Both the parties have decided to fund a Phase 1 trial investigating OSI-906 as a single agent and in conjunction with the proteasome inhibitor bortezomib to treat relapsed

Biovista expects to utilize its Clinical Outcomes Search Space (COSS) platform and multi-dimensional profiling capabilities to identify new treatments that reflect patients’ individual pathophysiological characteristics. The ‘p-medicine’ project

Mylan Pharma has launched the drug under its collaboration pact with Coastal Pharmaceuticals. The drug is the generic version of Endo Pharmaceuticals‘ Percodan tablets, used as a treatment

The expanded facility’s bed capacity has been increased by 50%. The facility houses a sample processing laboratory for human ADME studies. The UK regulatory authority – the Medicines

Burkert and BBS said QuickCONNECT offers short sterilisation times, lower water consumption and higher product yields leading to improved process returns. The BBS Sterile QuickCONNECT System employs standard

As a result of this, SBIO can now independently drive the development of its lead JAK2 program. Recent data from phase 2 clinical trials of SB1518 indicated promising

The ‘301 patent is directed to identifying small molecules that are affected by using metabolomics. It provides a method to evaluate chemical agents for drug effects and toxicity,

The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the company’s